The startup develops small molecule therapies that target synthetic lethal metabolic dependencies in cancer by disrupting stress response pathways essential for cancer cell survival. This approach enables patients to inhibit specific pathways that contribute to cancer cell growth, potentially improving treatment outcomes.

Alveron Pharma was a pharmaceutical company that has ceased all operations as of 30 April 2026 and currently offers no products, services, or active offerings.

Artica Therapeutics uses covalent chemistry to develop orally bioavailable small‑molecule inhibitors that achieve antibody‑like potency and selectivity for autoimmune and inflammatory diseases. By forming irreversible bonds with disease‑relevant proteins, its “insurmountable” drugs maintain target engagement even under high stimulation, offering a convenient oral alternative to injectable biologics.

Atriva Therapeutics develops first-in-class host-targeting therapies, specifically zapnometinib, to treat severe viral infections such as influenza and COVID-19 by modulating the host's immune response. The company addresses the need for effective antiviral treatments in the face of emerging respiratory viruses, with promising results from completed Phase I and Phase II clinical trials.

ATRO Medical is developing the Artimis® meniscus prosthesis, a polymer implant designed to replace the meniscus in patients experiencing chronic knee pain after meniscectomy. This solution aims to restore functionality and reduce pain, allowing patients to return to daily activities without the need for knee replacement surgery.

Balance is a digital payments platform that streamlines B2B transactions by offering features such as instant credit decisioning, flexible payment terms, and automated accounts receivable management. This solution reduces processing costs and enhances the purchasing experience for both buyers and vendors across the supply chain.

Cardiac Booster develops a next-generation, high-flow, low-profile percutaneous ventricular assist device (pVAD). This minimally invasive device provides temporary hemodynamic support for patients experiencing cardiogenic shock or undergoing high-risk PCI. The technology aims to improve patient outcomes by offering effective cardiac assistance with reduced procedural invasiveness.

EsoBiotec develops in vivo engineered CAR-T cell therapies that empower the immune system to target and eliminate cancer cells, significantly reducing treatment costs and improving patient access. Their approach minimizes the risk of graft-versus-host disease and streamlines hospital processes, enhancing the overall patient experience in cancer care.

FundaMental Pharma develops first-in-class NMDAR/TRPM4 interface inhibitors that selectively eliminate neurotoxic effects of extrasynaptic NMDA receptors while preserving synaptic receptor functions essential for neuronal survival and memory. This approach targets neurodegeneration, aiming to restore cognitive function and maintain overall brain health.

Gradient Denervation Technologies is developing a minimally invasive ultrasound-based catheter system for the transvascular treatment of pulmonary hypertension in heart failure patients. This technology targets elevated pulmonary vascular resistance, aiming to improve cardiovascular health and patient outcomes.

The startup offers an online hiring platform that enables businesses to recruit and manage remote interns and staff through integrated tools for task management, attendance tracking, and messaging. This platform facilitates efficient communication and collaboration for remote teams, providing young graduates with opportunities to work for international companies.

Indigo is an AI-powered home transaction platform that centralizes communication, bidding, and contract management for real estate agents, buyers, and sellers, enhancing transparency and efficiency throughout the transaction process. By automating contract generation and providing real-time analytics, Indigo reduces communication time by 80% and increases offer acceptance rates, streamlining the home buying and selling experience.

InnoSIGN utilizes OncoSIGNal pathway activity profiling technology to quantify cell signaling pathways in cancer, enhancing the understanding of disease mechanisms. This approach enables the translation of molecular data into functional cell behavior, improving personalized treatment strategies for cancer patients.

Labs develops human-enhancement technologies that utilize artificial intelligence, immersive realities, and consumer-wearables to foster community engagement and improve individual capabilities. The company addresses the need for interconnected social experiences and sustainable practices by providing tools that empower users to learn, create, and collaborate effectively.

LEA utilizes AI and optical character recognition (OCR) technology to extract and classify financial data from various documents, enabling registered investment advisors (RIAs) to efficiently access their clients' complete financial profiles. This streamlined process reduces the cost of delivering targeted financial advice, allowing advisors to focus on high-value interactions and growth opportunities.

Lo provides a platform for managing and automating commercial real estate leasing workflows. It centralizes lease documentation, tracks key dates, and streamlines communication between landlords and tenants. This system helps commercial property managers reduce administrative overhead and ensure compliance across their portfolio.

Nx provides a build system optimized for monorepos, featuring plugins for popular frameworks and advanced CI capabilities such as remote caching and task distribution. It addresses the inefficiencies of traditional CI systems by significantly reducing build times and costs, enabling developers to ship products faster and more reliably.

Pan Cancer T develops TCR-T cell therapies that utilize genetically modified T cells to target and eliminate tumor cells based on specific intracellular antigens in solid cancers. The company focuses on 30 unique tumor-restricted targets to enhance the durability and efficacy of treatments for hard-to-treat solid tumors, including triple-negative breast cancer.

RA UNLIMITED harnesses solar photovoltaic technology to generate clean and affordable electricity for homes, businesses, and communities in the Philippines. The company addresses the reliance on fossil fuels by providing sustainable energy solutions that create jobs and enhance the quality of life for Filipinos.

Ro operates a telehealth platform that provides online clinics for weight loss, sexual health, hair restoration, and fertility management using clinically proven treatments and prescription medications. The service eliminates the need for insurance and offers free, discreet shipping, making healthcare accessible and convenient for over 2 million members.

Salvia BioElectronics develops a bioelectronic therapy for individuals suffering from chronic migraine and cluster headache. Their MySalvia Therapy utilizes an ultra-thin implant activated by a wearable device to provide drug-free neuromodulation relief. This technology aims to allow millions of people to manage their neurological pain without interruption to daily life.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

The startup develops fusion proteins that target regulatory mechanisms involved in inflammatory and neuropathic pain, normalizing pain responses and inhibiting inflammation. This approach provides patients with access to pharmaceutical solutions that demonstrate efficacy in multiple pre-clinical models.

Tacalyx is a biotech company focused on developing anti-TACA therapies that specifically target tumor-associated carbohydrate antigens in cancer cells. This approach aims to improve the specificity and efficacy of cancer treatments, providing more effective therapeutic options for oncology patients.